Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Minerva Neurosciences ( (NERV) ) has provided an announcement.
At its annual meeting of stockholders held on December 22, 2025, Minerva Neurosciences, Inc. secured broad shareholder approval for a series of measures expanding its equity and capital flexibility, including an amendment to its 2013 Equity Incentive Plan to add 12,500,000 shares for potential issuance. Stockholders re-elected two directors to terms running until the 2028 annual meeting, approved doubling the company’s authorized common shares from 125 million to 250 million, authorized the issuance of common stock upon conversion of Series A Convertible Voting Preferred Stock in line with Nasdaq rules, endorsed executive compensation on an advisory basis, and ratified Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2025, collectively reinforcing management’s governance, financing capacity and incentive structures.
The most recent analyst rating on (NERV) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Minerva Neurosciences stock, see the NERV Stock Forecast page.
Spark’s Take on NERV Stock
According to Spark, TipRanks’ AI Analyst, NERV is a Underperform.
The overall stock score for Minerva Neurosciences is driven by significant financial instability, marked by negative equity and a lack of revenue. While the valuation suggests potential undervaluation, the financial risks present significant concerns. Technical indicators show some short-term positivity, but long-term trends are not favorable. The absence of earnings call and corporate events data means these factors do not influence the score.
To see Spark’s full report on NERV stock, click here.
More about Minerva Neurosciences
Minerva Neurosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, with its capital structure centered on common stock and Series A Convertible Voting Preferred Stock listed on Nasdaq.
Average Trading Volume: 3,015,236
Technical Sentiment Signal: Hold
Current Market Cap: $28.25M
For detailed information about NERV stock, go to TipRanks’ Stock Analysis page.